Compare Aon PLC (AON) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs Biogen Inc — how do they compare? Aon PLC trades at $353.5 (market cap $75.61B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Aon PLC is far larger — about 2.5× Biogen Inc's market cap, and Aon PLC pays a 0.92% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AON | BIIB | |
|---|---|---|
Market Cap | $75.61B | $30.13B |
Sector | Financials | Health |
52-Week High | $381.26 | $216.63 |
52-Week Low | $308.22 | $128.93 |
Enterprise Value | $90.22B | $37.20B |
Dividend Yield | 0.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.88, down 1.43% over the past day, with a neutral technical signal and support near $350. The company reported Q2 2026 EPS of $3.81, beating estimates, and has shown consistent revenue growth, reaching $17.18B in 2025. Profitability remains strong with a net income margin of 22.27% and ROE of 44.88%, though valuation ratios like P/E of 19.65 and P/S of 4.37 are elevated relative to historical averages.
The outlook is supported by analyst consensus with a $410 price target and 47% buy ratings, but risks include high debt levels and modest organic growth. Recent news highlights institutional buying and strategic appointments, yet some analysts caution on valuation. Earnings momentum and margin expansion provide upside potential if execution continues.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
